BRPI0417116A - usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação - Google Patents

usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação

Info

Publication number
BRPI0417116A
BRPI0417116A BRPI0417116-0A BRPI0417116A BRPI0417116A BR PI0417116 A BRPI0417116 A BR PI0417116A BR PI0417116 A BRPI0417116 A BR PI0417116A BR PI0417116 A BRPI0417116 A BR PI0417116A
Authority
BR
Brazil
Prior art keywords
ondansetron
composition
inflammation
effective amount
topical treatment
Prior art date
Application number
BRPI0417116-0A
Other languages
English (en)
Inventor
Fabrizio Dolfi
Nadege Tremel
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of BRPI0417116A publication Critical patent/BRPI0417116A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

"USOS DE UMA QUANTIDADE EFICAZ DE ONDANSETRON E COMPOSIçãO PARA TRATAMENTO TóPICO DE UMA INFLAMAçãO". A presente invenção trata em geral do uso do ondansetron, seus sais e base, como um princípio ativo na fabricação de composições farmacêuticas, mais particularmente composições dermatológicas, destinadas ao tratamento antiinflamatório curativo e/ou profilático pela via tópica. Mais especificamente, a presente invenção preconiza o uso do Ondansetron, seus sais e base para tratar topicamente a rosácea, um distúrbio inflamatório da pele.
BRPI0417116-0A 2003-12-10 2004-12-06 usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação BRPI0417116A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52858703P 2003-12-10 2003-12-10
EP04291328A EP1600158A1 (en) 2004-05-26 2004-05-26 Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
PCT/EP2004/013841 WO2005058312A1 (en) 2003-12-10 2004-12-06 Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
BRPI0417116A true BRPI0417116A (pt) 2007-03-06

Family

ID=34931124

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417116-0A BRPI0417116A (pt) 2003-12-10 2004-12-06 usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação

Country Status (8)

Country Link
US (1) US20070148197A1 (pt)
EP (2) EP1600158A1 (pt)
JP (1) JP2007513907A (pt)
AU (1) AU2004298317A1 (pt)
BR (1) BRPI0417116A (pt)
CA (1) CA2545760A1 (pt)
MX (1) MXPA06006360A (pt)
WO (1) WO2005058312A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006019832A1 (en) * 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating hepatitis c
EP1933849B1 (en) * 2005-09-30 2016-10-26 Galderma S.A. Use of ivermectin in the treatment of ophthalmic pathologies
CA2644458A1 (en) * 2006-03-01 2007-09-07 Galderma Research & Development Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
FR2901704A1 (fr) * 2006-05-31 2007-12-07 Galderma Res & Dev S N C Snc Utilisation de l'azasetron pour le traitement de la rosacee, et compositions pharmaceutiques
FR2901702A1 (fr) * 2006-05-31 2007-12-07 Galderma Res & Dev S N C Snc Utilisation de granisetron pour le traitement de sous-types de la rosacee, et compositions pharmaceutiques
FR2901703B1 (fr) * 2006-05-31 2012-12-07 Galderma Res & Dev Utilisation de zatosetron pour le traitement de la rosacee, et compositions pharmaceutiques
WO2008022484A2 (de) * 2006-08-24 2008-02-28 Novasearch Ag Kombinationen von 5-ht3-rezeptor-antagonisten zur topischen behandlung von hauterkrankungen
EP2116237A1 (en) 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
CL2008002730A1 (es) * 2008-09-12 2008-10-24 Roberto Figueroa Liza Patricio Composicion farmaceutica dermatologica, de aplicacion topica, en forma de crema, gel, unguento, solucion, emulsion que comprende 1a 99% de pentoxifilina, 0,1 a 80% de crema base y 0,1 a 75% de liposomas, util para rosacea, trastornos con fotosensibil
US9233118B2 (en) 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US20210052490A1 (en) * 2019-08-20 2021-02-25 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
WO2000048597A1 (en) * 1999-02-18 2000-08-24 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
KR100393478B1 (ko) * 2000-03-29 2003-08-06 주식회사종근당 자가유화 매트릭스형 경점막·경피흡수제제
US7643874B2 (en) * 2001-10-24 2010-01-05 Power Paper Ltd. Dermal patch

Also Published As

Publication number Publication date
JP2007513907A (ja) 2007-05-31
MXPA06006360A (es) 2006-08-23
AU2004298317A2 (en) 2005-06-30
EP1600158A1 (en) 2005-11-30
US20070148197A1 (en) 2007-06-28
WO2005058312A1 (en) 2005-06-30
CA2545760A1 (en) 2005-06-30
EP1696908A1 (en) 2006-09-06
AU2004298317A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
Biswal et al. Topical application of honey in the management of radiation mucositis. A preliminary study
ES2846854T3 (es) Composiciones antisépticas que comprenden iones de plata y mentol y usos de las mismas
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0417116A (pt) usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação
BRPI0817804A8 (pt) Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
ATE361082T1 (de) Pharmazeutische zusammensetzung aus komplexen kohlenhydraten deren anwendung
BR0215102A (pt) Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
BR112015005339A8 (pt) uso de óleo de semente de fruta milagrosa como um ingrediente ativo
RU2012149863A (ru) Полисахарид семени тамаринда для применения в лечении микробных инфекций
BR0006024A (pt) Composição para o tratamento de inflamação e dor em mamìferos
JP2002526407A5 (pt)
CA2953785A1 (en) Topical compositions and methods for treating wounds
ATE442864T1 (de) Pharmazeutische zusammensetzung mit einem organopolysiloxan-elastomer und einem lösungsmittel-aktivwirkstoff
BR0314142A (pt) Composição administrável oralmente para melhoria da qualidade do cabelo ou da pele
BR0318343A (pt) composição tópica para administração transdérmica
BRPI0715361B8 (pt) uso de polietileno glicol em inflamação relacionada com doenças ou distúrbios tópicos e cicatrização de ferimento
CY1115914T1 (el) Δερματολογικες συνθεσεις που περιεχουν συνδυασμο υπεροξυγονουχων λιπιδιων και ψευδαργυρου και οι χρησεις τους ιδιαιτερα στη θεραπεια του ερπητα
BR112014005966A2 (pt) composições para o tratamento de úlceras periféricas de várias origens
BRPI0603258A (pt) composições para uso na pele
BRPI0415225A (pt) composições tópicas compreendendo telmesteìna para o tratamento de distúrbios dermatológicos
BR112022019493A2 (pt) Cocristal de gabapentina, cetoprofeno e lisina, composições farmacêuticas e seu uso médico
WO2016063265A3 (pt) Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos
BRPI1101039A2 (pt) composiÇço farmacÊutica tàpica para prevenÇço e tratamento do prurido otolàgico, mÉtodo de tratamento e uso
RU2007132165A (ru) Адапален для длительного лечения обыкновенных угрей
ES2562985B1 (es) Composición farmacéutica para el tratamiento de lesiones de la piel

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.